Učitavanje...

Efficacy and safety of low‐dose apatinib in ovarian cancer patients with platinum‐resistance or platinum‐refractoriness: A single‐center retrospective study

BACKGROUND: This study aimed to evaluate the efficacy and safety of apatinib with a low dose of 250 mg/d in the treatment of platinum‐resistant or platinum‐refractory ovarian cancer patients. METHODS: Patients with platinum‐resistant or platinum‐refractory ovarian carcinoma treated with 250 mg/d apa...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Med
Glavni autori: Chen, Wei, Li, Ziting, Zheng, Zhong, Wu, Xiaohua
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7433830/
https://ncbi.nlm.nih.gov/pubmed/32627959
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3282
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!